Document 0816
 DOCN  M9590816
 TI    Establishment and characterization of human immunodeficiency virus type
       1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from
       HIV-1-seropositive patients.
 DT    9509
 AU    Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR;
       Birx DL; Henry M. Jackson Foundation, Walter Reed Army Institute of;
       Research, Rockville, MD 20850, USA.
 SO    J Infect Dis. 1995 Jun;171(6):1420-30. Unique Identifier : AIDSLINE
       MED/95287031
 AB    Human immunodeficiency virus type 1 (HIV-1) gp160-, gp120-, and tetanus
       toxoid-specific CD4+ T lymphocyte lines were developed from 11
       HIV-1-seropositive volunteers enrolled in a vaccine therapy trial. Of
       the 20 HIV-1 envelope-specific T cell lines, 9 were challenged with a
       panel of overlapping peptides spanning the gp120LAI sequence. The most
       frequently recognized regions were amino acids 74-105 in the C1 region
       and 306-328 in the V3 region. When tested against a panel of divergent
       HIV-1 envelopes, 55% of the envelope-specific lines were able to
       recognize gp120MN, while only 22% recognized gp120SF2. Cytotoxicity
       testing with HIV-1 envelope antigen or peptides demonstrated killing by
       all 3 envelope-specific lines tested. Supernatants from 2 of 9 lines had
       high titers of p24 gag antigen, which did not seem to interfere with
       functional properties.
 DE    Amino Acid Sequence  Cell Line  Consensus Sequence  Cross Reactions
       Cytotoxicity, Immunologic  CD4-Positive T-Lymphocytes/*IMMUNOLOGY
       Double-Blind Method  Epitope Mapping  Gene Products, env/*IMMUNOLOGY
       Human  HIV Envelope Protein gp120/IMMUNOLOGY  HIV
       Seropositivity/*IMMUNOLOGY  HIV-1/*IMMUNOLOGY  Lymphocyte Transformation
       Molecular Sequence Data  Peptides/CHEMISTRY/IMMUNOLOGY  Protein
       Precursors/*IMMUNOLOGY  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).